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Abstract
Most patients with Cystic Fibrosis (CF) carry at least one allele with the F508del mutation, resulting in a CFTR chloride
channel protein with a processing, gating and stability defect, but with substantial residual activity when correctly sorted to
the apical membranes of epithelial cells. New therapies are therefore aimed at improving the folding and trafficking of
F508del CFTR, (CFTR correctors) or at enhancing the open probability of the CFTR chloride channel (CFTR potentiators).
Preventing premature breakdown of F508del CFTR is an alternative or additional strategy, which is investigated in this
study. We established an ex vivo assay for murine F508del CFTR rescue in native intestinal epithelium that can be used as a
pre-clinical test for candidate therapeutics. Overnight incubation of muscle stripped ileum in modified William’s E medium
at low temperature (26uC), and 4 h or 6 h incubation at 37uC with different proteasome inhibitors (PI: ALLN, MG-132,
epoxomicin, PS341/bortezomib) resulted in fifty to hundred percent respectively of the wild type CFTR mediated chloride
secretion (forskolin induced short-circuit current). The functional rescue was accompanied by enhanced expression of the
murine F508del CFTR protein at the apical surface of intestinal crypts and a gain in the amount of complex-glycosylated
CFTR (band C) up to 20% of WT levels. Sustained rescue in the presence of brefeldin A shows the involvement of a post-
Golgi compartment in murine F508del CFTR degradation, as was shown earlier for its human counterpart. Our data show
that proteasome inhibitors are promising candidate compounds for improving rescue of human F508del CFTR function, in
combination with available correctors and potentiators.
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Introduction
The Cystic Fibrosis Transmembrane Conductance Regulator
(CFTR), a cAMP- and cGMP-activated chloride channel, is
expressed in the apical membrane of various epithelia, including
airway, intestine, and exocrine glands [1,2,3]. Mutations in the
CFTR encoding gene cause the lethal autosomal recessive disorder
cystic fibrosis (CF). Currently there are more then 1800 mutations
identified in the CFTR gene (available at http://www.genet.
sickkids.on.ca/ or http://www.cftr2.org (includes clinical infor-
mation)), but a single mutation (F508del) is present on at least one
allele in 90% of the CF patients [4]. Both the human and the
mouse orthologs of F508del CFTR are temperature-sensitive
folding and trafficking mutants [5,6]. The mutant CFTR protein is
retained in the endoplasmatic reticulum (ER) through prolonged
association with molecular chaperones, ubiquitinated and retro-
translocated into the cytosol, and finally degraded by the ubiquitin
(Ub)-proteasome pathway as part of ER-associated degradation
(ERAD) [7,8,9,10]. In most cultured cell models and native
epithelia, a small portion of the F508del protein can escape the
quality control (QC) system of the ER, and subsequently undergo
complex glycosylation in the Golgi compartment and transfer to
the apical membrane of epithelial cells. The F508del protein at the
cell surface is active as a chloride channel, though with a strongly
reduced open probability and considerably higher turnover rate as
compared to wild type CFTR [8,11,12,13]. The instability of
rescued F508del CFTR was attributed to unfolding and
subsequent ubiquitination, endocytosis, and lysosomal degradation
by a peripheral protein QC system sharing multiple chaperones
and co-chaperones (e.g. UbcH5; CHIP; Hsp70/90) with the QC
in the ER [14]. Attempts to correct the F508del CFTR allele-
specific phenotype are currently focussed on the selection of
compounds that overcome the inefficient folding of the mutant
protein (correctors), or enhance the CFTR chloride channel
activity (potentiators) [15,16,17]. Small molecule correctors may
also act as pharmacological chaperones and enhance the cell-
surface stability of F508del-CFTR [13]. Partial rescue of the
human F508del CFTR protein has been demonstrated in cell
culture using different strategies. Initially, restoration of F508del
CFTR processing was accomplished by low temperature incuba-
tion [18,19]. Subsequently, competition with truncated CFTR
constructs [20,21], chemical chaperones [22,23], transcriptional
regulators [24], pharmacological chaperones (e.g. MPB, miglustat
[25], second-site aminoacid substitutions [26] or deletion of the
regulatory insertion in nucleotide binding domain 1 of CFTR [27]
proved to be effective. Numerous F508del potentiators and
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correctors have been identified by either high throughput
screening (HTS) or modification(s) of available lead compounds
[28,29,30,31,32,33]. Most of these studies have been performed
with primary or immortalised human airway cells in vitro. Recent
studies showed that the relative efficacy of different types of
correctors depends on the cell type and experimental context
[29,34]. This limits the predictive value of in vitro data for clinical
applications assays and stresses the importance of choosing models
that reflect the in vivo situation. Prior to expensive and potentially
harmful clinical trials, testing of a promising candidate in the
context of a fully differentiated organ is advisable. In this study we
have used the F508del (Cftrtm1Eur) mouse strain generated at the
Erasmus MC Rotterdam for this purpose [3,6,35]. In this model,
made by ‘hit and run’ homologous recombination, a F508del
mutant form of Cftr mRNA is present at normal expression levels
in all affected organs. To avoid complications related to
unfavourable pharmacokinetics of candidate correctors or poten-
tiators that may obscure effects on mutant CFTR activity during in
vivo application, a major effort in our laboratory has been to define
assay conditions allowing the study of F508del CFTR processing
and rescue in murine intestinal epithelium in maintenance culture
[36,37]. The assay we have developed can be used to study the
trafficking defect of the F508del protein in intact epithelial tissue.
Here we show for the first time that low temperature (26uC)
incubation induced the delivery of complex-glycosylated F508del
CFTR to the plasma membrane and full functional rescue of
CFTR activity in mouse intestinal mucosa. Furthermore, we show
that at physiological temperature this rescue action could be
mimicked by a variety of proteasome inhibitors (PIs). The latter
result contrasts with earlier reports using cell culture models [38],
but confirms a later study in a different immortalized cell
population [39]. This emphasizes the importance of our approach
to examine F508del CFTR rescue in fully differentiated tissue.
This preclinical study clearly demonstrates that interfering with
the proteolytic activity of the proteasome may restore CFTR
function in intact murine epithelium, and suggests that proteasome
inhibitors may have therapeutic potential for the treatment of CF
[40].
Materials and Methods
Materials
William’s E mediumTM with Glutamax was obtained from
Gibco-BRL. Insulin, dexamethasone, the chemicals for the
Ussing-chamber measurements forskolin , genistein, carbachol,
heat-stable E. coli enterotoxin (STa), 8-pCPT-cGMP, bradykinin,
ATP and the proteasome inhibitors N-Acetyl-Leu-Leu-Nle-CHO
(ALLN), MG-132 and brefeldin A (BFA) were purchased from
Sigma. The proteasome inhibitor epoxomicin was obtained from
Calbiochem. The ECL detection system was from Pierce.
Animals
All animal experiments were performed according to the
guidelines issued by the Dutch government concerning animal
care and work with genetically modified organisms, all breeding of
and experiments with normal and mutant animals were performed
under permission of the independent institutional animal care and
ethics committee of the Erasmus MC (DEC, program numbers
OZP 120-54-01; 120-07-05). The F508del CFTR (Cftrtm1Eur) mice
with a mixed background (1296FVB) were backcrossed for more
than 13 generations with FVB wild type animals. The animals
were fed solid food and acidified water ad libitum. Mortality and
weight reduction of mutant animals was below 10–15% compared
to normal littermates in this colony. All experiments were
performed with 12–18 weeks old, congenic FVB mice carrying
the F508del CFTR (Cftrtm1Eur d/d) mutation and wild type
littermates (Cftrtm1Eur +/+) as controls in parallel experiments.
Cftrtm1cam (FVB) knockout mice [35] were used as controls in
immunocytochemistry.
Ussing chamber experiments of murine intestine
Mouse ileum was excised under hypnorm/diazepam anaesthe-
sia. The animals were terminated with an overdose of anaesthetics.
The ileum was flushed with ice-cold modified Meyler’s solution
(105 mM NaCl, 4.7 mM KCl, 1.3 mM CaCl2, 1.0 mM MgCl2,
20.2 mM NaHCO3, 0.4 mM NaH2PO4, 10 mM HEPES), the
muscle-layer was removed and the tissue was mounted in the
Ussing- chamber. All experiments were done in duplicate. At the
serosal side glucose (10 mM) and indomethacin (10 mM) were
added throughout the whole experiment in order to serve as an
energy source and to reduce basal Cl2 secretion caused by
endogenous production of prostaglandins, respectively. After
reaching equilibrium, the short-circuit current (Isc) response to
the following compounds was recorded, added either mucosally
(M) or serosally (S): forskolin (10 mM, S), to provoke cAMP-
induced, CFTR-mediated anion secretion; genistein (100 mM,
S+M), acting as a potentiator of the F508del CFTR channel [41];
carbachol (200 mM, S), a Ca2-linked secretagogue acting mainly
through activation of basolateral K+ channels and enhancement of
the driving force for apical Cl2 exit [42]; and D-glucose (10 mM,
M), to measure Na+-coupled glucose uptake by the SGLT1
transporter in the intestinal villi.
Tissue incubation
After obtaining the initial Isc recordings (t = 0), the tissue was
incubated in gassed (95% O2/5% CO2) William’s E medium
TM
with Glutamax (Gibco-BRL) supplemented with penicillin/strep-
tomycin (100 U/ml), insulin (10 mg/ml) and dexamethasone
(20 mg/ml) under the following conditions: 1) Low temperature
incubation: 26uC for 4 h–14 h; 2) Incubation with proteasome
inhibitors at 37uC for 2 h–6 h: ALLN (20 mM), MG-132 (10 mM),
epoxomicin (1 mM), bortezomib (PS314, VelcadeTM, 8 nM,
courtesy University Hospital Innsbruck, Austria); 3) Incubation
with brefeldin A (BFA, 20 mg/ml) at 37uC. Each piece of ileum
was subjected to serial Ussing-chamber measurements to obtain
recordings at different time points. Effects of the compounds were
judged by the difference in Isc responses before and after
treatment.
Immunohistochemistry
Tissues were fixed in 4% (wt/vol) para-formaldehyde. Sections
(5 mm) were stained with the rodent-specific CFTR antibody
R3195 (1:500) as described elsewhere [6].
Preparation of tissue samples for Western-blotting
Epithelial cells from treated ileum were isolated by exposing the
tissue to vibration (Vibromixer type E1 from Chemap A.G.,
50 Hz, amplitude 1.5 mm). Crude microsomal membranes were
generated from the isolated enterocytes as described previously
[43]. Western-blots were prepared according to standard proce-
dures using the Bio-Rad Miniprotean apparatus system. Murine
CFTR was detected with the R3195 (1:1000) antibody using the
ECL detection system (PierceTM). HRP-conjugated secondary
antibody was detected by chemoluminescence and the imaged
bands (in particular CFTR band C and band B) were visualized on
light-sensitive imaging film (Biomax XAR film, Kodak) and
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quantified using a calibrated GS-800 densitometer (Bio-Rad) and
Quantity-one software (version 4.2.1; Bio-Rad).
Results
Complete functional rescue of F508del CFTR after low
temperature incubation
To test the efficacy of CFTR rescue compounds in murine
intestinal biopsies ex vivo, functional stability of the tissue under
maintenance culture conditions is a major challenge. The Cftrtm1eur
F508del CFTR homozygous mutant mice display a much reduced
but distinct residual CFTR mediated Cl2 secretion in ileal mucosa
under Ussing-chamber conditions [35]. Compared to mice
homozygous for the Cftrtm1Cam knockout allele in the same
background (FVB), there is a significant cAMP-induced secretory
Cl2 current (,20% of WT littermates) that can therefore be
attributed to residual activity of F508del mutant CFTR. However,
this response does not survive prolonged incubation at 37uC in
glucose-containing minimal salt medium (modified Meyler’s
solution) for .4 h. A considerable improvement of functional
survival could be reached by replacing the Meyler’s buffer by
William’s E-Glutamax medium supplemented with insulin (10 mg/
ml) and dexamethasone (20 mg/ml). Ussing-chamber measure-
ments of F508del murine tissue incubated at 37uC in William’s E
medium showed a gradual decrease of CFTR-dependent ion
transport activity of 40% after 8 hours and 60% after 19 hours of
incubation (not shown). However, no significant loss of current
response was seen after 4–6 h of incubation, indicating that short
term testing of CFTR potentiators and correctors in this ex vivo
assay is feasible.
The most common strategy to rescue the F508del CFTR
processing in cell culture experiments is exposure to low
temperature (26uC). We investigated the effect of reduced
temperature incubation on the forskolin/genistein-stimulated
Cl2 secretion of freshly excised murine intestinal tissue derived
from homozygous F508del mice and their wild type littermates.
The tissue was subjected to serial Ussing-chamber measurements
under short-circuit current conditions, and incubated at 26uC for
different periods. A representative tracing from experiments
involving two samples from six mutant and normal mice each,
shows temperature rescue of cAMP-dependent Cl2 secretion
(delta Isc) after 8 h of incubation (Figure 1A). Measurements at
different time points first show significant rescue after 8 h, and
maximal rescue to wild type levels at 14 h. (Figure 1B) and
persisted up to 48 h (data not shown). The Na+ -coupled glucose
uptake response, which was routinely measured as a CFTR
independent indicator of the viability of the tissue, was not
significantly altered after the prolonged incubations (N= 8; data
not shown). In contrast, the cAMP-provoked Cl-secretion in ileum
of wild type mice did not increase further during incubation at the
reduced temperature (Figure 1C). This outcome is in line with our
previous notion that the CFTR conductance is no longer rate-
limiting for trans-epithelial Cl2 transport at CFTR protein levels
above ,20% of non-CF controls [42].
After overnight low temperature incubation (14 h) of mutant
ileum also the CFTR dependent Cl2 secretory response to cGMP-
linked secretagogues (heat-stable enterotoxin, STa; 8-pCPT-
cGMP), purinergic agonists (ATP), and a non-cholinergic Ca2+-
linked agonist (bradykinin), were restored to near WT levels
(Figure 1C). Unexpectedly, there was no clear improvement of the
Ca2+ dependent secretory response to carbachol (Figure 1C).
However the Isc response to carbachol of WT ileum, but not to
any of the other secretagogues, was likewise strongly reduced upon
O/N low-temperature incubation (results not shown), suggesting
Figure 1. Functional rescue of murine F508del CFTR in mouse
ileum after low temperature incubation. Pieces of normal and
F508del mutant murine ileal mucosa were incubated for different times
at 26uC. The same piece of tissue was subjected to short- circuit current
measurements (Isc) at the start of the experiment (t = 0) and following
incubation in supplemented William’s E medium (4 h–14 h). A.
Representative tracing showing temperature rescue (14 h at 26uC) of
mutant F508del CFTR activity compared to 0 h. B. Time course of
temperature rescue of &: ileum from homozygous F508del-Cftr mice,
compared to %: WT ileum. Delta Isc represents the change in short-
circuit current from baseline after addition of forskolin plus genistein. C.
Overnight incubation (t = 14 h) of F508del CFTR ileal mucosa at low
temperature. Bioelectric characteristics of F508del ileum at t = 0, (%)
and after incubation at reduced temperature (26uC, t = 14 h, &). Delta
Isc represents the change in short-circuit current from baseline after
addition of carbachol (100 mM; S), STa (0.1 mM; M), 8-pCPT-cGMP
(50 mM; S), bradykinin (2 mM; S), or ATP (100 mM; M+S). N = 4–6 mice, 2
ileal pieces/mouse. Bars represent averages +/2 SD (N= 6 mice, 2
samples per mouse. * indicates significantly different from 0 h, P,0.01
by ANOVA).
doi:10.1371/journal.pone.0052070.g001
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that prolonged in vitro incubation results in the loss of carbachol-
specific signalling components, e.g. muscarinic receptors.
Maturation of murine F508del CFTR induced by low
temperature incubation
Core-glycosylated, immature CFTR (band B) is localized in the
endoplasmic reticulum (ER), whereas the complex glycosylated,
mature CFTR (band C) is present in compartments distal to the
Golgi, in sub-apical compartments and in the apical membrane of
epithelial cells. Crude membrane preparations isolated from
murine intestinal mucosa contain a mixture of ER and apical
membranes, and are suitable to determine the tissue content of
both immature (band B) and mature (band C) CFTR protein. As
shown in Figure 2, over 98% of the CFTR pool in ileal mucosa
from wild type mice consisted of band C, both before (t = 0 h) and
after (t = 14 h) low temperature incubation, as determined by
digital scanning (see methods) . In contrast, the western blots of
crude ileal membranes freshly isolated from homozygous F508del
Cftr mutant mice showed that more than 95% of the CFTR
protein content is band B (Figure 2, t = 0 h). This low band C
expression in intestinal membranes from F508del Cftr mice was
previously reported [6] and recently confirmed in isolated brush
border membranes [44]. However, following incubation for 14 h
at the reduced temperature a clear shift from band B to band C
occurs, indicative for enhanced maturation or reduced degrada-
tion of F508del CFTR at this temperature (Figure 2). The level of
F508del CFTR band C amounted to approximately 25% of the
wild type band C (N=4 independent experiments), which is
sufficient to account for the full restoration of trans-epithelial Cl2
secretory currents shown in Figure 1A.
Paraffin sections derived from wild type ileum prior to low-
temperature incubation showed apical CFTR protein staining in
the intestinal crypts and a less prominent staining in the apical
membrane of the villi (Figure 3A). After 14 h incubation at 26uC
an increase in apical CFTR protein expression was observed in
both the epithelial crypt and villus compartment (Figure 3B). Prior
to low-temperature rescue, the F508del CFTR protein expression
remained below the detection limit for immunostaining
(Figure 3C). However, after incubation at low temperature
(t = 14 h), surface expression of the F508del protein at the apical
border of intestinal crypts was readily detected, albeit at a
substantially lower level than in wild type mice (Figure 3D). Tissue
derived from Cftrtm1Cam CFTR knockout mice co-incubated on the
same slide was negative in all cases, indicative for the specificity of
the antibody (Figure 3E). These intestinal data confirm and extend
previous data from cultured gall bladder cells showing that murine
F508del CFTR, similar to the human ortholog, displays a
temperature sensitive processing defect [6]. Moreover, we establish
muscle-stripped ileal mucosa from Cftrtm1Eur mutant mice as a
platform to study ex vivo F508del correction in the context of fully
differentiated epithelium.
Proteasome inhibitors restore chloride secretion in
F508del intestine
Initially, pulse-chase experiments of CFTR transfected HEK
and CHO cells showed the accumulation of detergent-insoluble,
multi-ubiquitinylated CFTR molecules with no detectable increase
of folded CFTR after proteasome inhibition [38,45]. However,
more recent studies by Gentzsch et al. on the endocytic trafficking
of wild type and F508del CFTR in BHK cells demonstrated that
proteasome inhibitors can stabilize low temperature rescued
mutant protein by preventing lysosomal degradation and promot-
ing recycling of endocytosed CFTR back to the plasma membrane
[46]. Comparable results were presented by Vij et al in a similar
immortalized cell line [39].
These apparently contradictory studies prompted us to use our
ex vivo intestinal model for testing the ability of proteasome
inhibitors to rescue F508del CFTR function in native intestinal
epithelium. Muscle stripped ileum from homozygous mutant
Cftrtm1Eur mice was incubated at 37uC for two to six hours in
supplemented William’s E medium containing different protea-
some inhibitors (PIs), or vehicle alone as control. The forskolin plus
genistein induced short-circuit current (Isc) response was deter-
mined at t = 0 h and t = 4–6 h. As shown in Figure 4A, incubation
of F508del mutant ileum with the PI ALLN for 6 h resulted in a
full restoration of transepithelial anion secretion, up to wild type
values. Recovery by this PI at 37uC was two times faster than low
temperature rescue (Figure 1B).
All four different PIs tested in this assay significantly increased
the forskolin/genistein-stimulated CFTR mediated chloride secre-
tion, whereas incubation with vehicle only had no effect
(Figure 4B). After 4 h incubation at 37uC MG-132 caused an
approximately twofold gain in anion current. The 20S proteasome
specific PI’s epoxy-ketone epoxomicin and ALLN allowed
correction to ,60% of wild type responses at this time point.
Importantly, the clinically relevant PI compound PS341 (bortezo-
mib, VelcadeTM) showed a similar gain in anion secretion.
No significant change in the glucose response was observed in
all tissues tested indicating that inhibition of the proteasome had
no effect on tissue viability in our assay (Figure 4C).
Figure 2. Maturation of F508del protein at low temperature.
Pieces of ileal mucosa (,5 cm) isolated from WT or homozygous
F508del CF mice were mounted in large aperture tissue holders and
incubated at 26uC for 14 h under carbogen gassing. Subsequently,
epithelial cells were harvested by high-frequency vibration and a crude
membrane fraction was isolated and subjected to SDS-PAGE (20 mg
protein/lane). Wild type (WT) and F508del Cftr was detected by Western
blotting using the R3195 (1:1000) antibody. A representative result of
four different experiments is shown. Band intensities were estimated by
digital scanning (see Methods), showing an increase of F508del CFTR
band C to approximately 25% (+/25 SEM, N=4) of wild type levels.
doi:10.1371/journal.pone.0052070.g002
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Maturation of murine F508del CFTR is enhanced by
proteasome inhibitors
The increase of cAMP-dependent chloride secretion in PI-
treated tissue was accompanied by the increased appearance of
mature, complex glycosylated (band C) CFTR in western blots.
Scanning of the gels showed that compared to carrier treated F508
CFTR, epoxomicin and MG-132 increased the band B intensity
twofold and the band C intensity three to fourfold (Figure 5 A).
Incubation with ALLN for 2, 4 and 6 hrs likewise resulted in a
time-dependent increase of band C, and a significant increase in
the band C/band B ratio from 0.08 to 0.36 and 4.8 respectively
(Figure 5B). As shown in Figure 4A and B, this partial rescue of
F508del CFTR band C after 6 hr and 4 hr ALLN is sufficient for
near hundred and sixty percent of normal forskolin response
respectively. As inferred from a calibration plot of WT-CFTR
(Figure 5A), the intensity of the F508del CFTR band C after
6 hours of ALLN treatment was about 20% of the value found in
epithelial membranes from WT ileum. In contrast to epoxomicin
and MG-132, ALLN treatment did not result in a significant gain
in the amount of CFTR band B (Fig. 5B), suggesting that ALLN is
a comparatively less effective inhibitor of proteasome function.
Importantly, the increase in band B levels following epoxomicin or
MG-132 treatment did not result in an enhanced CFTR function
compared to ALLN (Figure 4), arguing against unconventional
Figure 3. F508del CFTR is detectable by immunostaining after
low temperature incubation. Immunohistochemical staining of
CFTR in ileum of wild type (WT, A and B) and homozygous F508del
(F508del, C and D) mice prior to (A,C) and following low temperature
incubation (t = 14 h, B, D). F508del CFTR is only detectable after low
temperature incubation. Ileal sections of homozygous Cftrtm1Cam (FVB)
knockout mice were used as negatieve controls for the immunostaining
(CF- KO, E). Magnifications: A, C, E: 4006 and B, D: 2006.
doi:10.1371/journal.pone.0052070.g003
Figure 4. Functional rescue of F508del CFTR in native ileal
mucosa after treatment with proteasome inhibitors. A. Repre-
sentative Isc tracing of ileum from homozygous mutant F508del mice in
the Ussing-chamber before (t = 0 h) and after treatment with the
proteasome inhibitor ALLN (t = 6 h). Residual forskolin and genistein
mediated chloride secretion at the start of the experiment (t = 0 h) was
observed in all experiments. The dotted line indicates the average short
circuit current level following forskolin/genistein addition for WT ileum
(N= 24). ALLN treatment resulted in complete correction of CFTR
activity compared to wild type. B. Ileal mucosa from F508del/F508del
mutant mice was mounted in Ussing- chamber holders and incubated
under carbogen gassing in William’s E medium for 4 h at 37uC in the
presence of vehicle (DMSO, 0.1%), MG-132 (10 mM), epoxomicin (1 mM ),
PS341 (30 nM) or ALNN (20 mM). Subsequently the Isc response to
forskolin plus genistein was measured in Ussing chambers. C. At the
end of each measurement the viability of each sample was tested by
addition of 10 mM glucose to the mucosal bath. The average glucose
response after treatment with the various proteasome inhibitors is not
significantly different from the vehicle control. All experiments were
performed with N=4 mice, two samples per mouse. Averages plus or
minus SD are shown, statistical analysis was by one way ANOVA with
Tukey post hoc test for multiple averages, *: indicates significantly
different P,0.05 from vehicle).
doi:10.1371/journal.pone.0052070.g004
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trafficking of core-glycosylated CFTR to the luminal surface under
these conditions [47].
Proteasome inhibitors increase apical F508del CFTR
antigen in ileal enterocytes
Intestinal mucosa exposed to PIs in vitro and analysed in the
Ussing-chamber were fixed in 4% para-formaldehyde overnight,
embedded in paraffin and stained with the R3195 anti-CFTR
antibody [6]. Immunostaining of CFTR protein in untreated or
vehicle-treated F508del intestine remained below detection level
(Figure 6B, H), confirming present (Figure 3) and previous results
[35]. However, following 4 h exposure to epoxomicin (Figure 6D)
or PS341 (Figure 6G), apical staining of F508del CFTR was
clearly detectable in the crypt compartment, the site of CFTR
biogenesis in the intestinal epithelium. After 4 h exposure to MG-
132 (Figure 6 E) or ALLN (Figure 6 F), apical localization of
murine F508del CFTR protein was observed, also in the lower
villus region.
Rescue of F508del CFTR ion transport function by ALLN
in the intestine occurs at the post-Golgi level
The rescue of F508del CFTR mediated anion secretion by PIs
could take place at the level of the ER, e.g. by inhibition of ERAD
[48], or in post-ER compartments, e.g. by stabilizing the mutated
protein in the apical membrane [14]. In an attempt to discriminate
between both possibilities, we measured the functional rescue of
F508del CFTR in the presence of brefeldin A (BFA). BFA blocks
protein transfer from the ER to the Golgi system but does not
affect the trans-Golgi network (TGN), and therefore prevents the
transfer of F508del CFTR from the ER but not from the trans
Golgi system to the apical membrane. We first rescued F508del
CFTR in mouse ileum by incubation with ALLN for 4 h at 37uC,
resulting in a substantial increase of CFTR dependent short-circuit
current (Figure 7). Subsequently, the tissue was exposed for 2
additional hours to ALLN alone, BFA alone, or BFA plus ALLN,
and the effect on transepithelial anion secretion was measured in
the Ussing-chamber. In the absence of BFA, ALLN further
enhanced cAMP-stimulated anion secretion up to the level
observed in WT ileum, either by preventing F508del CFTR
degradation in the ER, or by stabilizing a pool of F508del CFTR
in the apical membrane. Inhibition of Golgi to apical membrane
traffic by BFA alone resulted in a rapid return of ALLN-rescued
anion secretion back to pre-ALLN levels. This rapid loss of the
rescued F508del CFTR in the apical compartment in the presence
of BFA could be prevented at least partially by ALLN. This is
consistent with the existence of an ALLN-sensitive post-Golgi
degradation pathway for murine F508del CFTR in intestinal cells.
In summary, these data show that inhibition of the proteasome
leads to a substantial improvement of murine F508del CFTR
protein expression, maturation and function and demonstrate that
the ubiquitin-proteasome pathway is involved in the degradation
of murine F508del CFTR in native epithelium.
Discussion
Here we describe an ex vivo assay applied to muscle-stripped
mouse intestinal mucosa that can be used to test experimental
therapies aimed at improving the function of F508del CFTR. First
we demonstrate that complete functional rescue of the murine
F508del CFTR activity can be achieved in this model by
incubation of the tissue at low temperature (Figure 1). The
functional rescue was accompanied by partial rescue of F508del
CFTR protein maturation, as shown by western blotting (Figure 2)
and immuno-histochemistry (Figure 3). As a demonstration of an
effective pharmaceutical approach we show here that incubation
of mutant ileal mucosa with four different proteasome inhibitors at
physiological temperature (ALLN, epoxomicin, MG-132, PS341/
bortezomib) also results in substantial rescue of the mature
F508del CFTR protein and of its anion transport function
(Figures 4–7). As expected from the exceptionally high turnover
rate of small intestinal epithelium in comparison with other
epithelial tissues, 2–3 days in mice and 5 days in humans [49],
biosynthesis of CFTR in the intestinal crypts must be relatively
fast, to explain the kinetics of F508del CFTR rescue by low
temperature (maximal at 8 h) or in the presence of PIs (maximal at
4 h) found in this study.
Figure 5. Improved CFTR maturation after treatment with
proteasome inhibitors. Pieces of ileal mucosa (,5 cm) isolated from
homozygous F508del CF mice were mounted in large aperture tissue
holders and exposed for 4 h (panel A) or 2–6 h (panel B) at 37uC to
various PIs (see legend Fig. 4). Subsequently, epithelial cells were
harvested by high-frequency vibration and a crude membrane fraction
was isolated and subjected to western blot analysis of CFTR as
described in Methods. Autoradiographs of 3 independent experiments
were scanned, representative figures are shown here. Slots were loaded
with equal amounts of protein to facilitate comparison. Panel A, left:
dilution series of crude membranes derived from wild type mice (WT;
20, 10 and 4 mg protein/lane) used to calibrate the intensity of the wt
CFTR signal. Panel A, right: crude membranes (20 mg protein) derived
from homozygous F508del mice treated for 4 h with epoxomicin
(1 mM); vehicle (0.1%DMSO), or MG-132 (10 mM). Average band C
intensity increased from 5% (vehicle) to 20% (epoxomicin) and 15%
(MG-132) of WT. Band B intensity increased twofold after epoxomicin
and MG-132, compared to vehicle. Panel B: Crude membranes from
wild type mice (WT; 20 mg protein/lane); F508del: crude membranes
derived from homozygous F508del mice, untreated (lane 1); following
low temperature incubation (26uC, t = 14 h) (lane 2); after treatment at
37uC with ALLN (20 mM) for 2 h (lane 3); 4 h (lane 4); and 6 h (lane 5).
Band C/Band B ratio increased from 0.08 (2 h) to 0,36 (4 h) and 4,8
(6 hr).
doi:10.1371/journal.pone.0052070.g005
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Our data indicate that degradation of misfolded CFTR by the
proteasome, or by a process indirectly linked to proteasome
function, is the major mechanism accounting for the instability of
murine F508del CFTR in native intestinal epithelium. Further-
more, the effect of brefeldin A on ALLN induced rescue (Figure 7)
suggests that PI-sensitive degradation is not limited to the ER, but
also occurs in a post ER compartment, most plausibly involving
the peripheral protein quality control system [14].
Previous studies of CFTR degradation have been performed
mainly in immortalised human cell culture models. ER associated
degradation (ERAD) of F508del CFTR was found to involve the
ubiquitin-proteasome pathway [50]. Additionally, the activity of
an ATP independent-pathway has been suggested that is
responsible for the degradation of misfolded F508del CFTR
[45]. Studies of proteasome inhibitors in these model systems did
show stabilisation of band B but failed to demonstrate improved
maturation to band C [38,45].
Our data extend these reports by showing that in the context of
differentiated mouse cells efficient functional correction by PI’s of
murine F508del CFTR does occur. This raises the question
whether in differentiated human cells in situ this can be observed as
well, and whether PI’s can contribute to the treatment of CF in
humans.
Here, we clearly demonstrate in native mouse intestine that
proteasome inhibitors are capable of preventing degradation of
murine F508del CFTR in the murine enterocyte, allowing the
accumulation of fully mature F508del CFTR and partial or full
restoration of transepithelial chloride secretion. Furthermore, our
data obtained with brefeldin A (Figure 7) suggest that murine
F508del CFTR rescue by PI’s occurs at least in part at the post-
Figure 6. Effect of proteasome inhibitors on CFTR immunostaining. Histochemical staining of CFTR in ileum from FVB wild type mice (A);
ileum from untreated homozygous Cftrtm1Eur F508del mice (B); ileum from homozygous Cftrtm1Cam knockout mice (C); PI-treated ileum from
homozygous Cftrtm1Eur F508del mice (D–G); ileum was treated for 4 h at 37uC with 1 mM epoxomicin (D), 10 mM MG-132 (E), 20 mM ALLN (F), or 30 nM
PS341 (G). Panel H: Vehicle-treated (0.1% DMSO) ileum from homozygous Cftrtm1Eur (FVB) F508del mice. Magnifications: 2006.
doi:10.1371/journal.pone.0052070.g006
Figure 7. ALLN rescue of F508del CFTR function persists in the
presence of brefeldin. Short-circuit current responses to forskolin
plus genistein were measured in stripped ileum from homozygous
mutant Cftrtm1eur mice (t = 0 h), and again after 4 h of incubation with
ALLN as described in the legend of Fig. 4 (4 h). The tissues were then
incubated for an additional 2 h in the presence of ALLN alone (closed
circles), ALLN plus BFA (closed squares) or BFA alone (closed triangles).
At t = 6 h the tissues were again analysed in the Ussing-chamber. Delta
Isc represents the change in short-circuit current from baseline after
addition of forskolin and genistein (average6SEM of 3 experiments). All
three averages at 6 hrs are significantly different (P,0.05 by one way
ANOVA, with Tukey post hoc test for multiple averages).
doi:10.1371/journal.pone.0052070.g007
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Golgi level, presumably involving stabilization of the surface pool
of F508del CFTR. Such a rescue mechanism is expected to be
more prominent in species and tissues showing partial processing
of F508del CFTR, as demonstrated here for the mouse intestine
by the occurrence of a considerable F508del CFTR dependent
trans-epithelial anion secretion (,20% of wild type) and of mature
F508del-CFTR protein on western blots (band C; ,5% of WT;
Fig. 2, 5) in the absence of any treatment.
Mechanisms of PI induced F508del CFTR rescue
Recent studies have shown that F508del CFTR folding
efficiency is highly sensitive to secondary mutations in the CFTR
sequence [51,52], and further dependent on the multiple
interactions with the large number of proteins that constitute the
folding and quality control system of the cell (‘The Cloud’) [10]. It
is no surprise therefore that F508del CFTR folding efficiency
depends both on the cellular context and the CFTR sequence
[53]. This likely also applies to other critical stages of the CFTR
life cycle: transfer through the Golgi, glycosylation, insertion and
recycling at the plasma membrane. At each of these levels PI’s
potentially have an effect on F508del CFTR turnover either
through a direct interaction with ubiquitin tagged CFTR, or
indirectly though affecting the turnover of a key factor in the
proteostasis machinery. It is conceivable, therefore, that PI’s will
have a different effect on human airway or intestinal cells in situ
than in immortalised cells in culture. A PI induced accumulation
of the CFTR precursor (band B) as observed in cultured human
cells, was also observed with epoxomicin and MG-132 in our
system (figure 5A). This may by itself not be sufficient for
functional correction, but is likely show synergy with a suitable
folding corrector and activator. Moreover, is seems likely that
stabilisation of corrected human F508del CFTR at the apical
membrane also occurs. Together this may increase the level of
correction to levels required for clinical benefit. Indeed, Gentzsch
et al.showed, most recently in a model of differentiated human
airway epithelial cells that surface derived normal and F508del
CFTR is recycled through endocytosis [46,54]. The mutant form
is recycled less efficiently, and is retained and subsequently
degraded in sub-apical vesicles. Moreover, the internalization and
lysosomal breakdown of this surface pool of mutant CFTR could
be largely prevented by incubation with PI’s [54]. In a related
study it was shown by Lukacs et al. that improperly folded
domains in F508del CFTR are recognised at the plasma
membrane by the Hsc70/Hsp90 chaperone system, which allows
CHIP mediated ubiquitination, internalisation and finally degra-
dation of mutant CFTR in the lysosomes [14]. The mechanism by
which PIs cause retention of mutant CFTR at the cell surface is
still unclear but may involve inhibition of the ubiquination step
initiating the internalization of F508del CFTR at the apical
membrane, possibly by depletion of free ubiquitin [54].
Recent data by Maiuri et al. redefine CF as a deficiency of
autophagy. They show that abnormal trafficking of human
F508del CFTR in cell culture and murine F508del CFTR can
be effectively rescued by ROS scavengers and inhibition of
transglutaminase [55], which increases the efficacy of CFTR
activators [56]. Future studies will be required to establish the
effect of PIs on this process, which would offer an alternative
explanation for PI induced rescue of mutant F508del CFTR
CFTR.
A further alternative explanation for the functional rescue of
F508del CFTR in native intestinal epithelium was also considered,
i.e. PI stimulation of ER stress and of the unfolded protein
response (UPR), possibly resulting in cell surface trafficking of
core-glycosylated CFTR through an unconventional pathway
[47]. While we can not completely rule out this explanation,
several findings argue against the operation of this mechanism
under our conditions. First, ALLN has no apparent effect on the
steady-state level of F508del CFTR band B (Figure 5B), whereas
functional rescue was observed (Figure 4B). Further, all PI’s tested
increase the level of F508del CFTR band C, in clear contrast to
the absence of such effects under conditions of ER stress [47].
Finally, a twofold increase of band B observed following exposure
to the PI inhibitors Epoxomicin and MG-132 (Figure 5 A) was not
paralleled by an enhanced functional rescue of F508del-CFTR in
comparison with ALLN treatment (Figure 4B).
Additional experiments including a more detailed analysis of PI
effects on the peripheral quality control system for mutant-CFTR
in native mouse epithelium, and studies of F508del-CFTR rescue
by PIs in native human intestinal epithelium (e.g. rectal biopsies or
organoids) are needed to confirm our concept and to explore the
applicability of PIs for the rescue of F508del-CFTR processing and
function in CF patients.
Anti-inflammatory action of proteasome inhibitors
Vij et al. recently showed that nano-particle mediated intranasal
delivery of the proteasome inhibitor Velcade/Bortezomib reduced
the LPS induced inflammatory response in CFTR KO mice [57].
This was attributed to inhibition of the NFkB pathway, though a
reduction of IkBa inactivation. Vij et al. have previously provided
evidence that CFTR deficiency results in activation of the NFkB
pathway [58,59]. These studies show the feasibility and efficacy of
PS341 (Velcade/Bortezomib) delivery in vivo, and combined with
our data suggest that a therapeutic effect of proteasome inhibitors
in CF pathology can be expected at two interrelated levels, first
functional rescue of F508del CFTR processing (this paper, [39])
and further reduction of NFkB activity [40]. Further studies are
required to establish whether the effect of PI’s on F508del CFTR
folding and trafficking may be due to a PI induced reduction of
NFkB, which may have an effect on the ER and peripheral QC
system.
Towards clinical application of proteasome inhibitors in
CF
Proteasome inhibitors interfere with multiple cellular processes.
Therefore, their therapeutic usefulness for the treatment of CF
might be questioned. However, the recent development of peptide
boronates made the clinical use of proteasome inhibitors feasible
[60]. Preclinical studies in vitro and in vivo using the proteasome
inhibitor PS341 (Bortezomib, VelcadeTM) demonstrated its anti-
tumor activity in models for hematological malignancies and solid
tumors [61]. PS341 can be used effectively at low concentrations,
and clinical trials conducted in patients with refractory hemato-
logical malignancies reported antitumor activity with manageable
treatment related problems [62,63,64]. Patients with advanced
solid tumors also benefit from PS341-based combination therapies
[65]. More recently, promising results were reported in an animal
model with MLN9708, a molecular variant of PS341 with better
bioavailability [66,67].
Our data show that PS431 treatment increased the cAMP
dependent chloride secretion in F508del murine intestine
(Figure 4B), and a distinct increase in apical CFTR antigen
(Figure 6G), with no significant effect on glucose response
(Figure 4C) or tissue morphology (Figure 6G). Further develop-
ment of proteasome inhibitors for long term clinical applications
[68], is therefore not only a priority in the field of oncology but
also in the field of CF.
Current reports highlight the cell type specific differences in
response to pharmaceutical intervention at the level of F508del-
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CFTR processing. Furthermore the response to correctors varies
considerably between cell pools from different donors [29,34].
Previously, variations of clinical phenotype in patients homozy-
gous for F508del, were shown to correlate with differences in
residual F508del CFTR activity [69,70]. Together, this suggests
that in the F508del patient population significant differences in the
kinetics of processing and recycling of CFTR can occur. It seems
likely, therefore that for clinical benefit in specific F508del CF
patients we need to define an optimal combination of agonists,
correctors, potentiators and possibly proteasome inhibitors, which
act on different levels of the CFTR processing and recycling
machinery [10,51,52].
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